Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939653 · ClinicalTrials.gov registry record · Phase 2
T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)
A Phase 2 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT00939653: Clinical Trial Phase 2 study, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
NCT00939653 is a Phase 2 study that was terminated before completion, run by Therapeutic Advances in Childhood Leukemia Consortium. The registered enrollment target is 6 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939653, a Phase 2 study, was terminated before completion, sponsored by Therapeutic Advances in Childhood Leukemia Consortium.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
Primary Outcome
Disease response assessed after chemotherapy from bone marrow aspirates/biopsies and complete blood count.
Interventions
- DRUG Cyclophosphamide
- DRUG Etoposide
- DRUG Cytarabine
- DRUG Filgrastim
- DRUG Clofarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-07-10 |
| Est. Completion | 2011-07-15 |
| Phase | Phase 2 |
Why NCT00939653 stopped before completion
NCT00939653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT00939653 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00939653 about?
NCT00939653 is a clinical study titled "T2007-002 Clofarabine, Etoposide, Cyclophosphamide in Relapsed Acute Myelogenous Leukemia (AML)". Clofarabine is a drug approved by the FDA (Food and Drug Administration) for treating children (age 1-21) with leukemia. This research study will use clofarabine with two other cancer fighting drugs. Clofarabine will be used together with etoposide (VePesid®, VP-16) and cyclophosphamide (Cytoxan®).
What is the current status of trial NCT00939653?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2009-07-10. Estimated completion is 2011-07-15.
What interventions are being tested in trial NCT00939653?
The interventions under investigation include: Cyclophosphamide (DRUG), Etoposide (DRUG), Cytarabine (DRUG), Filgrastim (DRUG), Clofarabine (DRUG).
Who is sponsoring clinical trial NCT00939653?
This trial is sponsored by Therapeutic Advances in Childhood Leukemia Consortium, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00939653's enrollment target sits among peer trials
6 1996th of 2000 higher than 1 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI